P-003: EVALUATION OF TREATMENT PATTERN, HEALTHCARE RESOURCE UTILIZATION AND COSTS OF ILLNESS FOR SICKLE CELL DISEASE IN GHANA: A PRIVATE MEDICAL INSURANCE CLAIMS DATABASE STUDY

Documenti analoghi

• “Does the dose of hydroxyurea correlate with shorter hospital stay and higher fetal hemoglobin levels in patients with sickle cell disease?”
  di: Musa Fares Alzahrani, et al.
  Pubblicazione: (2026-12-01)
• P-003: EVALUATION OF TREATMENT PATTERN, HEALTHCARE RESOURCE UTILIZATION AND COSTS OF ILLNESS FOR SICKLE CELL DISEASE IN GHANA: A PRIVATE MEDICAL INSURANCE CLAIMS DATABASE STUDY
  di: DEI-ADOMAKOH Y., et al.
  Pubblicazione: (2022-08-01)
• Clinical Utility of Neutrophil to Lymphocyte Ratio in Sickle Cell Disease With Vaso-Occlusive Crisis
  di: Satish Maharaj, et al.
  Pubblicazione: (2023-01-01)
• Current and Future Therapeutics for Treating Patients with Sickle Cell Disease
  di: Mariam Barak, et al.
  Pubblicazione: (2024-05-01)
• The GLOBE Trial: Efficacy and Safety of L-Glutamine Plus Hydroxyurea Versus Hydroxyurea Alone in Sickle Cell Anemia - A Double-Blind, Randomized Study
  di: Nader Shakibazad, et al.
  Pubblicazione: (2026-06-01)